Sheng, J., Luo, H., Liu, X., Liu, C., Zhou, W., Zhao, Y., . . . Liu, W. Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): A prospective, single-arm, phase II study. Nature Publishing Group.
Chicago Style (17th ed.) CitationSheng, Jindong, et al. Tislelizumab (anti-PD-1) Plus Chemotherapy as Neoadjuvant Therapy for Patients with Stage IB3/IIA2 Cervical Cancer (NATIC): A Prospective, Single-arm, Phase II Study. Nature Publishing Group.
MLA (9th ed.) CitationSheng, Jindong, et al. Tislelizumab (anti-PD-1) Plus Chemotherapy as Neoadjuvant Therapy for Patients with Stage IB3/IIA2 Cervical Cancer (NATIC): A Prospective, Single-arm, Phase II Study. Nature Publishing Group.
Warning: These citations may not always be 100% accurate.